Shares of Opthea Ltd. (OPT) touched a 52-week high of $5.90 last week, signaling growing investor optimism as the company approaches key phase III clinical trial milestones in the coming months.
Australia-based Opthea is a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases. Its lead investigational product is Sozinibercept, a novel, first-in-class VEGF C/D inhibitor to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with any standard-of-care anti-VEGF A therapy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com